Cullinan Therapeutics Inc.
10
5
9
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
10.0%
1 terminated/withdrawn out of 10 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Role: lead
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Role: lead
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Role: lead
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Role: lead
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Role: lead
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
Role: lead
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Role: lead
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Role: lead
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Role: lead
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Role: lead
All 10 trials loaded